Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade
Checkpoint inhibitors targeting programmed cell death protein 1 (PD-1)/programmed death-
ligand 1 (PD-L1) have revolutionized cancer therapy across many indications including …
ligand 1 (PD-L1) have revolutionized cancer therapy across many indications including …
Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1+ T lymphocyte niches through a feed-forward loop
Y Hua, G Vella, F Rambow, E Allen, AA Martinez… - Cancer Cell, 2022 - cell.com
The lack of T cell infiltrates is a major obstacle to effective immunotherapy in cancer.
Conversely, the formation of tumor-associated tertiary-lymphoid-like structures (TA-TLLSs) …
Conversely, the formation of tumor-associated tertiary-lymphoid-like structures (TA-TLLSs) …
[HTML][HTML] PD-L1-mediated immune evasion in triple-negative breast cancer is linked to the loss of ZNF652
Y Liu, Y Peng, W Du, C Yu, Z Peng, L Qin, Y Ma, X Wu… - Cell Reports, 2023 - cell.com
The intrinsic regulation of programmed death ligand-1 (PD-L1) expression remains unclear.
Here, we report that zinc-finger protein 652 (ZNF652) is a potent transcription repressor of …
Here, we report that zinc-finger protein 652 (ZNF652) is a potent transcription repressor of …
A signature of enhanced proliferation associated with response and survival to anti-PD-L1 therapy in early-stage non-small cell lung cancer
In early-stage non-small cell lung cancer, the combination of neoadjuvant anti-PD-L1 and
subablative stereotactic body radiation therapy (SBRT) is associated with higher rates of …
subablative stereotactic body radiation therapy (SBRT) is associated with higher rates of …
[HTML][HTML] Machine learning-based risk model incorporating tumor immune and stromal contexture predicts cancer prognosis and immunotherapy efficacy
LN He, H Li, W Du, S Fu, T Chen, X Zhang, C Chen… - Iscience, 2023 - cell.com
The immune and stromal contexture within the tumor microenvironment (TME) interact with
cancer cells and jointly determine disease process and therapeutic response. We aimed at …
cancer cells and jointly determine disease process and therapeutic response. We aimed at …
Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1 T lymphocyte niches through a feed-forward loop
M Duhamel, A Takeda, S Jalkanen, S Junius… - Cancer Cell, 2022 - lilloa.univ-lille.fr
The lack of T cell infiltrates is a major obstacle to effective immunotherapy in cancer.
Conversely, the formation of tumor-associated tertiary-lymphoid-like structures (TA-TLLSs) …
Conversely, the formation of tumor-associated tertiary-lymphoid-like structures (TA-TLLSs) …
New Approaches Targeting Immuno-oncology and Tumor Microenvironment
D Zhu, F He - Cancer Treatment: An Interdisciplinary Approach, 2022 - Springer
Immune checkpoint blockade therapy is now a key tool in the war against cancer. Antibody
medications, such as anti-PD-1 and anti-PD-L1, have several clear benefits, including broad …
medications, such as anti-PD-1 and anti-PD-L1, have several clear benefits, including broad …
The Immune Landscape and Therapy of Upper Tract Urothelial Carcinoma
K Evmorfopoulos, V Tzortzis, PJ Vlachostergios - 2023 - Springer
Urothelial carcinomas (UCs) are a group of malignancies with high prevalence in Western
countries. Among patients diagnosed with UC, approximately 5–10% present with upper …
countries. Among patients diagnosed with UC, approximately 5–10% present with upper …